TimesSquare Capital Management’s AtriCure ATRC Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q2
Sell
-854,547
Closed -$26M 160
2024
Q1
$26M Sell
854,547
-121,563
-12% -$4.07M 0.38% 102
2023
Q4
$34.8M Buy
976,110
+71,275
+8% +$2.65M 0.51% 85
2023
Q3
$39.6M Buy
904,835
+254,655
+39% +$12.4M 0.62% 72
2023
Q2
$32.1M Sell
650,180
-127,675
-16% -$5.88M 0.46% 95
2023
Q1
$32.2M Sell
777,855
-182,175
-19% -$7.56M 0.47% 92
2022
Q4
$42.6M Sell
960,030
-4,500
-0.5% -$188K 0.61% 75
2022
Q3
$37.7M Buy
964,530
+61,951
+7% +$2.83M 0.52% 92
2022
Q2
$36.9M Buy
902,579
+170,269
+23% +$8.07M 0.51% 90
2022
Q1
$48.1M Sell
732,310
-188,900
-21% -$12.2M 0.54% 82
2021
Q4
$64.1M Sell
921,210
-29,400
-3% -$2.14M 0.57% 75
2021
Q3
$66.1M Sell
950,610
-111,390
-10% -$8.57M 0.58% 62
2021
Q2
$84.2M Sell
1,062,000
-266,665
-20% -$19.4M 0.69% 43
2021
Q1
$87.1M Sell
1,328,665
-78,379
-6% -$4.83M 0.75% 35
2020
Q4
$78.3M Buy
1,407,044
+114,379
+9% +$4.95M 0.64% 51
2020
Q3
$51.6M Buy
1,292,665
+117,155
+10% +$4.97M 0.48% 84
2020
Q2
$52.8M Buy
+1,175,510
New +$51.2M 0.5% 81

Other funds holding ATRC

TimesSquare Capital Management's ATRC Position: Q2 2024 in Review

TimesSquare Capital Management sold out of AtriCure (ATRC) in Q2 2024, closing a stake of 854,547 shares — an estimated $26M sold.

TimesSquare Capital Management first reported a position in ATRC in Q2 2020 and held it in 16 quarters. The position peaked at $87.1M in Q1 2021. 197 funds tracked by Wall St. Rank hold ATRC as of Q2 2024.

  • TimesSquare Capital Management reported no remaining AtriCure position as of Q2 2024 after selling out during the quarter.
  • TimesSquare Capital Management sold 854,547 AtriCure shares in Q2 2024, an estimated $26M.
  • TimesSquare Capital Management first reported a position in AtriCure in Q2 2020 and held it in 16 quarters.
  • TimesSquare Capital Management's AtriCure position peaked at $87.1M in Q1 2021.
  • 197 funds tracked by Wall St. Rank held AtriCure as of Q2 2024.

Based on TimesSquare Capital Management's 13F filing for Q2 2024, filed 8 Aug 2024.